CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


We found 6218 result(s)

New at CADTH - November 2020

Last Updated: November 12, 2020
Result type: Reports
Product Line: New at CADTH

News and Events CADTH’s 2020 Virtual Symposium: A Success! CADTH successfully wrapped up our first-ever virtual Symposium that was held on November 9 and 10, 2020. With more than 1,500 people in attendance, a diverse group of stakeholders gathered to discuss health care decision-making in an age of uncertainty, with health technology expert...

Sevelamer in Patients with End-stage Renal Disease: A Systematic Review and Economic Evaluation

Last Updated: November 10, 2006
Result type: Reports

Technology Sevelamer hydrochloride oral capsule. Condition Patients with end-stage renal disease (ESRD) and hyperphosphatemia Issue Traditional (calcium-based) phosphate binders may not be perceived as suitable for controlling hyperphosphatemia in all patients because of theoretical concerns about their use, and dose-limiting hypercalcemia....

Point-of-Care Anticoagulation Monitoring Devices: A Better Alternative?

Last Updated: February 7, 2007
Result type: Reports

CADTH’s health technology assessment report on point-of-care anticoagulation monitoring devices examines the clinical and cost effectiveness of point-of-care devices used to monitor long-term oral anticoagulation therapy. How well do these devices work? Do they offer value-for-money or cost savings to the health care system? Are there factors, s...

Continuous Renal Replacement Therapy in Adult Patients with Acute Renal Failure: Systematic Review and Economic Evaluation

Last Updated: June 28, 2007
Result type: Reports

Technology and Condition Continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD) in critically ill adult patients with acute renal failure (ARF). There are 2,445 cases of ARF requiring dialysis among critically ill Canadian patients per year. Issues CRRT is a more costly therapy that has theoretical advantages over stan...

Atypical Antipsychotic Monotherapy for Schizophrenia: Clinical Review and Economic Evaluation of First Year of Treatment

Last Updated: October 1, 2007
Result type: Reports

Technology and Condition Widely available atypical antipsychotics (AAPs) (risperidone, olanzapine, quetiapine, and clozapine) for treatment of schizophrenia. Issue Prescription medication costs for schizophrenia – driven by the use of AAPs – increased from C$48.13 million in 1996 to C$150 million in 2004. Health funders and practitioners need...

Recombinant human growth hormone for Turner syndrome: systematic review and economic evaluation

Last Updated: December 21, 2007
Result type: Reports

Technology and Condition Recombinant human growth hormone (rhGH) for treatment of Turner syndrome (TS). Issue Given the high cost of rhGH treatment and the evolving evidence base for its clinical effect in patients with TS, policy makers need evidence
to inform reimbursement decisions about rhGH. Methods and Results A system...

Reprocessing Single-Use Medical Devices in Canada

Last Updated: February 28, 2008
Result type: Reports

CADTH's two-part health technology assessment report series on reprocessing of Single-Use Devices (SUDs) addresses concerns about possible risks to patients of infection or other complications, legal liability issues, and uncertainties regarding cost-effectiveness. The first report summarizes findings from a Canadian survey of acute-care hospita...

  • Project Number: 334

Hip Protectors in Long-Term Care: A Clinical and Cost-Effectiveness Review and Primary Economic Evaluation

Last Updated: May 26, 2008
Result type: Reports
Research Type: Devices and Systems

Context and Policy Issues Over 300,000 Canadians reside in long-term care (LTC) facilities. Hip injuries in these residents are a health concern. Each year approximately 50% of them fall at least once, and 5% to 10% of these falls will result in fractures. The one-year mortality rate following a hip fracture is about 20%. The societal cost in t...